Thor Medical ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	0.44	-	-	-
Other Revenue	0.4	-	-	-
Revenue	0.84	-	-	-
Gross Profit	0.84	-	-	-
Selling, General & Admin	29.65	13.29	3.14	-
Other Operating Expenses	19.92	28.26	3.69	-
Operating Expenses	70.49	43.93	7.16	-
Operating Income	-69.65	-43.93	-7.16	-
Interest Expense	-0.6	-0.1	-	-
Interest & Investment Income	6.63	1.45	2.02	-
Currency Exchange Gain (Loss)	1.36	0.24	-0.25	-
Other Non Operating Income (Expenses)	0	-0.3	-0.17	-
Pretax Income	-62.27	-42.64	-5.56	-
Income Tax Expense	-4.26	-0.43	-	-
Earnings From Continuing Operations	-58.01	-42.21	-5.56	-
Earnings From Discontinued Operations	-	-	-21	-311.24
Net Income	-58.01	-42.21	-26.56	-311.24
Net Income to Common	-58.01	-42.21	-26.56	-311.24
Shares Outstanding (Basic)	332	236	175	115
Shares Outstanding (Diluted)	332	236	175	115
Shares Change (YoY)	40.80%	34.90%	51.82%	-
EPS (Basic)	-0.17	-0.18	-0.15	-2.70
EPS (Diluted)	-0.17	-0.18	-0.15	-2.70
Free Cash Flow	-120.65	-24.12	-64.09	-414.71
Free Cash Flow Per Share	-0.36	-0.10	-0.37	-3.60
Gross Margin	100.00%	-	-	-
Operating Margin	-8301.91%	-	-	-
Profit Margin	-6914.42%	-	-	-
Free Cash Flow Margin	-14379.98%	-	-	-
EBITDA	-50.13	-41.96	-6.83	-
D&A For EBITDA	19.52	1.97	0.33	-
EBIT	-69.65	-43.93	-7.16	-
Revenue as Reported	0.84	-	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.